yodiyim/iStock via Getty Images
- Juvena Therapeutics said that it is collaborating with Eli Lilly (NYSE:LLY) for a global license to develop, and bring to market, new drug candidates aimed at enhancing muscle health.
- According to the agreement, Juvena will benefit from an upfront payment, an equity investment, and additional milestone payments tied to development and commercialization success.
- As part of the deal, Juvena will provide Eli Lilly with exclusive rights to the identified lead candidates, while Lilly will take on the roles of further research, development, and commercialization.
More on Eli Lilly
- Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- Eli Lilly: If You Don’t Buy On Weight Loss Promise Now, You Probably Never Will
- Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
- Drugmakers complain clarity lacking from administration on lowering drug prices
- Eli Lilly is said to have posted 60% rise in obesity drug sales in India last month